| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| NVSNovartis AG | 321.75B | 168.62 | 23.45 | 5.97% | 24.9% | 30.04% | 5.5% | 0.80 |
| OGNOrganon & Co. | 1.9B | 7.29 | 10.13 | -2.92% | 3.01% | 20.64% | ||
| SRXHSRx Health Solutions Inc. | 8.71M | 0.13 | -0.19 | 28.4% | -9.36% | 13.22% |
Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.
| Sep 2022 | Sep 2023 | |
|---|---|---|
| Sales/Revenue | 92.63M | 118.94M |
| Revenue Growth % | - | 28.4% |
| Cost of Goods Sold | 79.33M | 95.33M |
| COGS % of Revenue | 85.64% | 80.15% |
| Gross Profit | 13.31M | 23.61M |
| Gross Margin % | 14.36% | 19.85% |
| Gross Profit Growth % | - | 77.45% |
| Operating Expenses | 14.47M | 29.42M |
| OpEx % of Revenue | 15.62% | 24.73% |
| Selling, General & Admin | 13.14M | 29.49M |
| SG&A % of Revenue | 14.19% | 24.8% |
| Research & Development | 0 | 0 |
| R&D % of Revenue | - | - |
| Other Operating Expenses | 1.33M | -75.1K |
| Operating Income | -1.17M | -5.81M |
| Operating Margin % | -1.26% | -4.88% |
| Operating Income Growth % | - | -397.9% |
| EBITDA | -539.4K | -4.1M |
| EBITDA Margin % | -0.58% | -3.45% |
| EBITDA Growth % | - | -660.81% |
| D&A (Non-Cash Add-back) | 627.01K | 1.7M |
| EBIT | -1.17M | -8.76M |
| Net Interest Income | -753.71K | -2.05M |
| Interest Income | 0 | 0 |
| Interest Expense | 753.71K | 2.05M |
| Other Income/Expense | -842.77K | -5.13M |
| Pretax Income | -2.01M | -10.94M |
| Pretax Margin % | -2.17% | -9.2% |
| Income Tax | 440.21K | 196.58K |
| Effective Tax Rate % | 121.91% | 101.8% |
| Net Income | -2.45M | -11.14M |
| Net Margin % | -2.64% | -9.36% |
| Net Income Growth % | - | -354.72% |
| Net Income (Continuing) | -2.45M | -11.14M |
| Discontinued Operations | 0 | 0 |
| Minority Interest | 0 | 0 |
| EPS (Diluted) | -3.48 | -0.90 |
| EPS Growth % | - | 74.14% |
| EPS (Basic) | -3.48 | -0.90 |
| Diluted Shares Outstanding | 704.18K | 12.39M |
| Basic Shares Outstanding | 704.18K | 12.39M |
| Dividend Payout Ratio | - | - |
| Sep 2022 | Sep 2023 | |
|---|---|---|
| Total Current Assets | 14.8M | 25.13M |
| Cash & Short-Term Investments | 1.66M | 2.07M |
| Cash Only | 1.66M | 2.07M |
| Short-Term Investments | 0 | 0 |
| Accounts Receivable | 3.38M | 7.06M |
| Days Sales Outstanding | 13.32 | 21.66 |
| Inventory | 4.02M | 5.72M |
| Days Inventory Outstanding | 18.48 | 21.9 |
| Other Current Assets | 5.31M | 9.56M |
| Total Non-Current Assets | 19.99M | 39.38M |
| Property, Plant & Equipment | 7.36M | 10.64M |
| Fixed Asset Turnover | 12.59x | 11.18x |
| Goodwill | 8.78M | 18.48M |
| Intangible Assets | 3.78M | 9.79M |
| Long-Term Investments | 0 | 0 |
| Other Non-Current Assets | 61.54K | 473.41K |
| Total Assets | 34.79M | 64.51M |
| Asset Turnover | 2.66x | 1.84x |
| Asset Growth % | - | 85.46% |
| Total Current Liabilities | 22.04M | 65.5M |
| Accounts Payable | 13.58M | 24.36M |
| Days Payables Outstanding | 62.51 | 93.28 |
| Short-Term Debt | 5.66M | 34.6M |
| Deferred Revenue (Current) | 0 | 0 |
| Other Current Liabilities | 1.88M | 5.2M |
| Current Ratio | 0.67x | 0.38x |
| Quick Ratio | 0.49x | 0.30x |
| Cash Conversion Cycle | -30.71 | -49.73 |
| Total Non-Current Liabilities | 11.82M | 5.3M |
| Long-Term Debt | 8.99M | 0 |
| Capital Lease Obligations | 2.3M | 3.57M |
| Deferred Tax Liabilities | 0 | 0 |
| Other Non-Current Liabilities | 529.99K | 1.73M |
| Total Liabilities | 33.86M | 70.8M |
| Total Debt | 17.85M | 39.38M |
| Net Debt | 16.19M | 37.31M |
| Debt / Equity | 19.25x | - |
| Debt / EBITDA | - | - |
| Net Debt / EBITDA | - | - |
| Interest Coverage | -1.55x | -2.83x |
| Total Equity | 927.48K | -6.29M |
| Equity Growth % | - | -778.15% |
| Book Value per Share | 1.32 | -0.51 |
| Total Shareholders' Equity | 927.48K | -6.29M |
| Common Stock | 7.27M | 8.8M |
| Retained Earnings | -6.34M | -17.58M |
| Treasury Stock | 0 | 0 |
| Accumulated OCI | 0 | 2.49M |
| Minority Interest | 0 | 0 |
| Sep 2022 | Sep 2023 | |
|---|---|---|
| Cash from Operations | 4.67M | 3.87M |
| Operating CF Margin % | 5.04% | 3.25% |
| Operating CF Growth % | - | -17.16% |
| Net Income | -2.45M | -11.14M |
| Depreciation & Amortization | 1.33M | 2.87M |
| Stock-Based Compensation | 0 | 2.95M |
| Deferred Taxes | 0 | 0 |
| Other Non-Cash Items | 7.31M | 15.35M |
| Working Capital Changes | -1.53M | -6.16M |
| Change in Receivables | 565.47K | -4.96M |
| Change in Inventory | -1.89M | -746.55K |
| Change in Payables | 0 | 0 |
| Cash from Investing | -6.83M | -19.78M |
| Capital Expenditures | -244.72K | -1.27M |
| CapEx % of Revenue | 0.26% | 1.07% |
| Acquisitions | -5.67M | -13.23M |
| Investments | - | - |
| Other Investing | -914.45K | -5.28M |
| Cash from Financing | 3.8M | 16.43M |
| Debt Issued (Net) | 3.91M | 11.38M |
| Equity Issued (Net) | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Share Repurchases | 0 | 0 |
| Other Financing | -107.88K | 5.06M |
| Net Change in Cash | 1.66M | 519K |
| Free Cash Flow | 3.13M | 1.58M |
| FCF Margin % | 3.38% | 1.32% |
| FCF Growth % | - | -49.73% |
| FCF per Share | 4.45 | 0.13 |
| FCF Conversion (FCF/Net Income) | -1.91x | -0.35x |
| Interest Paid | 0 | 0 |
| Taxes Paid | 0 | 0 |
| Metric | 2022 | 2023 |
|---|---|---|
| Return on Equity (ROE) | -264.09% | - |
| Return on Invested Capital (ROIC) | -5.11% | -18.09% |
| Gross Margin | 14.36% | 19.85% |
| Net Margin | -2.64% | -9.36% |
| Debt / Equity | 19.25x | - |
| Interest Coverage | -1.55x | -2.83x |
| FCF Conversion | -1.91x | -0.35x |
| Revenue Growth | - | 28.4% |
Explore detailed financial history, valuation models, and returns analysis
DCF models, peer multiples & analyst estimates
Historical returns with dividends reinvested
Yield, growth, payout safety & DRIP calculator
EPS trends, net income & profitability analysis
Long-term charts & historical price data
Sales growth patterns & revenue breakdown
30 years of valuation, profitability & efficiency metrics